Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions

Sponsor: Qingdao Central Hospital
Study ID: NCT07090525
Phase: PHASE2
Status: Recruiting

Apply to this trial

Conditions

Overall Response Rate

Eligibility Criteria

Sex: ALL
Age: N/A - N/A
Healthy Volunteers: Not accepted

Interventions

Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2 — DRUG
Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2, repeat use on 21st day if the serous effusion not controlled
cisplatin 40mg/m2 intracavity injection — DRUG
cisplatin 40mg/m2 intracavity injection

Study Details

The purpose of this study is to explore the efficacy and safety ofof bevacizumab plus cisplatin compare with cisplatin in the treatment of malignant serous effusion in patients with advanced adenocarcinoma

Key Dates

First listed: Jul 29, 2025
Start date: Jul 1, 2025
Status verified: Jul 2025
Primary completion: Dec 1, 2026
Completion: May 1, 2027

Study Design

Enrollment: 60 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: bevacizumab plus cisplatin arm
Active Comparator: cisplatin arm
cisplatin 40mg/m2 intracavity injection

Primary Outcome Measure

overall response [ Time Frame: 4 weeks ]

Central Contacts

youxin ji director of oncology, md, phD
86-53268665078
[email protected]